Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer (original) (raw)

paper cover icon

Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer

Journal of Clinical Oncology, 2016

Jonathan HungJonathan Hung

Abstract

e16519Background: Castration resistant prostate cancer (CRPC) continues to present a challenge for oncologists. There is renewed interest in the use of docetaxel in advanced prostate cancer; howeve...

Jonathan Hung hasn't uploaded this paper.

Let Jonathan know you want this paper to be uploaded.

Ask for this paper to be uploaded.